Isofol Medical: Potential expansion into autism - Redeye

Redeye comments on Isofol’s expansion of its arfolitixorin license to include autism spectrum disorders, specifically targeting cerebral folate deficiency. We view this as an interesting early-stage strategic option, supported by growing regulatory validation of folate-based therapies, although still at a preclinical stage.

Länk till analysen i sin helhet: https://www.redeye.se/research/1157398/isofol-medical-potential-expansion-into-autism?utm_source=finwire&utm_medium=RSS